IL162203A0 - Indolinone derivatives useful as protein inase inhibitors - Google Patents

Indolinone derivatives useful as protein inase inhibitors

Info

Publication number
IL162203A0
IL162203A0 IL16220302A IL16220302A IL162203A0 IL 162203 A0 IL162203 A0 IL 162203A0 IL 16220302 A IL16220302 A IL 16220302A IL 16220302 A IL16220302 A IL 16220302A IL 162203 A0 IL162203 A0 IL 162203A0
Authority
IL
Israel
Prior art keywords
sup
derivatives useful
indolinone derivatives
protein
inase inhibitors
Prior art date
Application number
IL16220302A
Other languages
English (en)
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of IL162203A0 publication Critical patent/IL162203A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL16220302A 2001-12-27 2002-12-20 Indolinone derivatives useful as protein inase inhibitors IL162203A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34381301P 2001-12-27 2001-12-27
US34374601P 2001-12-27 2001-12-27
PCT/US2002/041252 WO2003057690A1 (fr) 2001-12-27 2002-12-20 Derives d'indolinone utilises comme inhibiteurs de la proteine kinase

Publications (1)

Publication Number Publication Date
IL162203A0 true IL162203A0 (en) 2005-11-20

Family

ID=26993599

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16220302A IL162203A0 (en) 2001-12-27 2002-12-20 Indolinone derivatives useful as protein inase inhibitors

Country Status (22)

Country Link
US (3) US6686362B2 (fr)
EP (1) EP1458713B1 (fr)
JP (1) JP4363985B2 (fr)
KR (1) KR100965519B1 (fr)
CN (1) CN1290844C (fr)
AT (1) ATE302771T1 (fr)
AU (1) AU2002360753B2 (fr)
BR (1) BR0215360A (fr)
CA (1) CA2470480C (fr)
CO (1) CO5611126A2 (fr)
DE (1) DE60205776T2 (fr)
DK (1) DK1458713T3 (fr)
ES (1) ES2247411T3 (fr)
HK (1) HK1068886A1 (fr)
HU (1) HUP0500111A3 (fr)
IL (1) IL162203A0 (fr)
MX (1) MXPA04006271A (fr)
NO (1) NO327550B1 (fr)
NZ (1) NZ533219A (fr)
PL (1) PL208283B1 (fr)
RU (1) RU2316554C2 (fr)
WO (1) WO2003057690A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7195876B2 (en) * 2002-08-09 2007-03-27 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
RU2006117635A (ru) * 2003-10-24 2007-12-10 Шеринг Акциенгезельшафт (De) Производные индолинона и их применение для лечения патологических состояний, таких как злокачественное новообразование
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス, インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
NZ595182A (en) 2005-10-18 2012-12-21 Janssen Pharmaceutica Nv Pharmaceutical uses of 4-cyano-1H-imidazole-2-carboxylic acid { 2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl} -amide
AU2007240437B2 (en) 2006-04-20 2012-12-06 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
BRPI0710548B8 (pt) 2006-04-20 2021-05-25 Janssen Pharmaceutica Nv inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica
US7928136B2 (en) 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011083124A1 (fr) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur flt3 destinés au traitement ou à la prévention de troubles douloureux
MX2012008083A (es) 2010-01-12 2012-08-15 Ab Science Inhibidores de triazol y oxazol quinaza.
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (fr) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Procédé pour la préparation de dérivés d'ester hétérocyclique
TWI569799B (zh) 2012-09-21 2017-02-11 安羅格製藥股份有限公司 抑制組成型活性磷酸化flt3激酶的方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
CA2956417C (fr) 2014-07-31 2022-09-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonistes des recepteurs flt3
EP3254698A1 (fr) 2016-06-08 2017-12-13 Universite De Montpellier Inhibiteur du récepteur flt3 à faible dose pour le traitement d'une douleur neuropathique
PE20191238A1 (es) 2016-11-02 2019-09-11 Arog Pharmaceuticals Inc Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado
CN111093640A (zh) 2017-05-17 2020-05-01 国家健康与医学研究院 用于改善阿片类药物疼痛治疗的flt3抑制剂
WO2019057649A1 (fr) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de la leucémie myéloïde aiguë
WO2022019998A1 (fr) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Formes cristallines de crénolanib et leurs procédés d'utilisation
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
AU759226B2 (en) 1998-05-29 2003-04-10 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
ES2192877T3 (es) * 1998-12-17 2003-10-16 Hoffmann La Roche 4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2.
JP2002533360A (ja) 1998-12-31 2002-10-08 スージェン・インコーポレーテッド 蛋白質キナーゼ活性を調節するためおよび癌の化学療法において用いるための3−ヘテロアリーリデニル−2−インドリノン化合物
DE19924401A1 (de) 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
ATE316527T1 (de) 1999-08-27 2006-02-15 Boehringer Ingelheim Pharma Substituierte indolinone als tyrosinkinase inhibitoren
EP1222187B1 (fr) 1999-10-06 2004-09-22 Boehringer Ingelheim Pharmaceuticals Inc. Composes heterocycliques utiles comme inhibiteurs de tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE19949209A1 (de) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2001042243A2 (fr) 1999-12-08 2001-06-14 Advanced Medicine, Inc. Inhibiteurs de proteine kinase
CZ303705B6 (cs) 2000-02-15 2013-03-27 Sugen, Inc. Pyrrolem substituovaná 2-indolinonová sloucenina pro pouzití jako inhibitor proteinkináz a farmaceutická kompozice s jejím obsahem
AU2001270260A1 (en) 2000-06-30 2002-01-14 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
CA2426440C (fr) 2000-08-18 2011-03-15 Millennium Pharmaceuticals, Inc. Derives de quinazoline utilises comme inhibiteurs de kinase
US6677368B2 (en) 2000-12-20 2004-01-13 Sugen, Inc. 4-aryl substituted indolinones
US7195876B2 (en) * 2002-08-09 2007-03-27 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
JP2007513967A (ja) 2003-12-11 2007-05-31 セラヴァンス, インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物

Also Published As

Publication number Publication date
JP2005514420A (ja) 2005-05-19
US7060703B2 (en) 2006-06-13
MXPA04006271A (es) 2004-10-04
DE60205776T2 (de) 2006-06-14
HUP0500111A2 (hu) 2005-07-28
AU2002360753B2 (en) 2008-08-21
CO5611126A2 (es) 2006-02-28
RU2004122918A (ru) 2005-03-27
CN1608063A (zh) 2005-04-20
CN1290844C (zh) 2006-12-20
JP4363985B2 (ja) 2009-11-11
US20030171378A1 (en) 2003-09-11
BR0215360A (pt) 2004-12-14
CA2470480A1 (fr) 2003-07-17
NZ533219A (en) 2005-10-28
DE60205776D1 (en) 2005-09-29
WO2003057690A1 (fr) 2003-07-17
US20040198804A1 (en) 2004-10-07
PL208283B1 (pl) 2011-04-29
US7223783B2 (en) 2007-05-29
NO20042926L (no) 2004-07-08
NO327550B1 (no) 2009-08-10
HUP0500111A3 (en) 2009-10-28
EP1458713A1 (fr) 2004-09-22
AU2002360753A1 (en) 2003-07-24
EP1458713B1 (fr) 2005-08-24
DK1458713T3 (da) 2005-10-31
KR100965519B1 (ko) 2010-06-23
PL369602A1 (en) 2005-05-02
US6686362B2 (en) 2004-02-03
HK1068886A1 (en) 2005-05-06
KR20040070283A (ko) 2004-08-06
ATE302771T1 (de) 2005-09-15
RU2316554C2 (ru) 2008-02-10
ES2247411T3 (es) 2006-03-01
US20060142281A1 (en) 2006-06-29
CA2470480C (fr) 2010-12-14

Similar Documents

Publication Publication Date Title
HK1068886A1 (en) Indolinone derivatives useful as protein kinase inhibitors
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
MY130363A (en) "pyrrole substituted 2-indolinone protein kinase inhibitors"
CA2366932A1 (fr) Inhibiteurs cycliques de proteine tyrosine kinase
MY126235A (en) 3-(4-amidopyrrol-2-ylmethylidene) -2- indolinone derivatives as protein kinase inhibitors.
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
IL110131A0 (en) Arylidene and heteroarylidene oxindole derivatives, their preparation and pharmaceutical compositions containing them
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
TW200621751A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
CY1111599T1 (el) Αναστολεις κινασης θειενοπυριδινης και φουροπυριδινης
CA2387351A1 (fr) Derives d'indole servant d'inhibiteurs de la tyrosine kinase
AU2464601A (en) Tricyclic protein kinase inhibitors
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
MXPA02010759A (es) Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
AU2002366563A1 (en) Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders
UA86083C2 (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors